​

Arcturus Therapeutics (ARCT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARCT Stock Forecast

Arcturus Therapeutics (ARCT) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $29.29, with a high of $48.00 and a low of $10.58. This represents a 178.16% increase from the last price of $10.53.

$10 $18 $26 $34 $42 $50 High: $48 Avg: $29.29 Low: $10.58 Last Closed Price: $10.53

ARCT Stock Rating

Arcturus Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (66.67%), 3 Hold (20.00%), 2 Sell (13.33%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 2 3 10 Strong Sell Sell Hold Buy Strong Buy

ARCT Price Target Upside V Benchmarks

TypeNameUpside
StockArcturus Therapeutics178.16%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$48.00$18.30
Last Closing Price$10.53$10.53$10.53
Upside/Downside-355.84%73.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2537---10
Mar, 2538---11
Feb, 2538---11
Jan, 2538---11
Dec, 2437---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 10, 2025Thomas ShraderBTIG$48.00$14.55229.90%355.84%
Nov 11, 2024Whitney IjemCanaccord Genuity$10.58$3.02250.33%0.47%
Aug 06, 2024Whitney IjemCanaccord Genuity$10.30$3.20221.88%-2.18%
Jul 02, 2024Ed ArceH.C. Wainwright$8.58$3.38153.85%-18.52%
May 31, 2024Yasmeen RahimiPiper Sandler$20.02$5.64254.96%90.12%
May 10, 2024Whitney IjemCanaccord Genuity$12.30$3.83221.15%16.81%
Mar 19, 2024Yale JenLaidlaw$11.30$4.83133.95%7.31%
Nov 02, 2022Gena WangBarclays$25.00$21.6915.26%137.42%
May 11, 2022Goldman Sachs$14.00$13.563.24%32.95%
Nov 09, 2021Madhu KumarGoldman Sachs$30.00$36.23-17.20%184.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2025BTIGBuyBuyhold
Oct 01, 2024Leerink PartnersBuyBuyhold
Sep 17, 2024Canaccord GenuityBuyBuyhold
Aug 07, 2024H.C. WainwrightBuyBuyhold
Jul 02, 2024Piper SandlerOverweightOverweighthold
Jul 02, 2024H.C. WainwrightBuyBuyhold
Jun 07, 2024William BlairOutperformOutperformhold
May 31, 2024Piper SandlerOverweightOverweighthold
May 29, 2024CitigroupBuyBuyhold
Mar 11, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.51$-7.86$0.35$-1.12$-3.00----
Avg Forecast$-3.02$-7.87$-5.83$-1.78$-2.43$-2.15$0.11$2.28$6.88
High Forecast$-2.11$-5.51$-3.24$-0.85$-1.41$8.61$0.94$19.58$15.94
Low Forecast$-4.49$-11.72$-11.86$-2.46$-3.03$-8.86$-0.32$-5.24$3.50
Surprise %16.23%-0.13%-106.00%-37.08%23.46%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.54M$12.36M$205.75M$157.75M$152.31M----
Avg Forecast$9.76M$23.84M$53.87M$173.81M$169.49M$205.12M$315.95M$451.96M$682.31M
High Forecast$13.43M$32.81M$96.72M$246.32M$200.06M$346.54M$322.82M$451.96M$1.37B
Low Forecast$7.50M$18.34M$35.43M$131.16M$152.63M$152.56M$309.09M$451.96M$424.08M
Surprise %-2.23%-48.17%281.91%-9.24%-10.14%----

Net Income Forecast

$-250M $-90M $70M $230M $390M $550M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.36M$-206.86M$9.35M$-29.73M$-80.94M----
Avg Forecast$-80.30M$-166.49M$-191.63M$-29.73M$-62.64M$-52.90M$8.24M$77.19M$183.29M
High Forecast$-56.19M$-133.19M$-153.30M$-23.78M$-37.63M$229.25M$25.06M$521.26M$424.36M
Low Forecast$-119.58M$-199.79M$-229.95M$-35.67M$-80.80M$-235.86M$-8.58M$-139.50M$93.11M
Surprise %-11.13%24.25%-104.88%-29.21%----

ARCT Forecast FAQ

Is Arcturus Therapeutics stock a buy?

Arcturus Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 3 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Arcturus Therapeutics is a favorable investment for most analysts.

What is Arcturus Therapeutics's price target?

Arcturus Therapeutics's price target, set by 15 Wall Street analysts, averages $29.29 over the next 12 months. The price target range spans from $10.58 at the low end to $48 at the high end, suggesting a potential 178.16% change from the previous closing price of $10.53.

How does Arcturus Therapeutics stock forecast compare to its benchmarks?

Arcturus Therapeutics's stock forecast shows a 178.16% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Arcturus Therapeutics over the past three months?

  • April 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Arcturus Therapeutics’s EPS forecast?

Arcturus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.15, marking a -28.33% decrease from the reported $-3 in 2024. Estimates for the following years are $0.11 in 2026, $2.28 in 2027, and $6.88 in 2028.

What is Arcturus Therapeutics’s revenue forecast?

Arcturus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $205.12M, reflecting a 34.67% increase from the reported $152.31M in 2024. The forecast for 2026 is $315.95M, followed by $451.96M for 2027, and $682.31M for 2028.

What is Arcturus Therapeutics’s net income forecast?

Arcturus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-52.902M, representing a -34.64% decrease from the reported $-80.941M in 2024. Projections indicate $8.24M in 2026, $77.19M in 2027, and $183.29M in 2028.